SAN DIEGO--(BUSINESS WIRE)--Engrail Therapeutics™ (Engrail) (the Company), a precision neuroscience company focused on the development of transformational therapies to improve the lives of patients, today announced the close of an oversubscribed $157 million Series B financing round. The round was co-led by new investors F-Prime Capital, Forbion, and Norwest Venture Partners, with participation from RiverVest Venture Partners, Red Tree Venture Capital, funds managed by abrdn Inc., Ysios Capital, Longwood Fund, Eight Roads Ventures, and existing founding investor Pivotal Life Sciences.

圣地亚哥--（商业新闻短讯）--Engrail Therapeutics™（Engrail）（该公司）是一家专注于开发转化疗法以改善患者生活的精密神经科学公司，今天宣布结束一轮超额认购的1.57亿美元B系列融资。新投资者F-Prime Capital、Forbion和Norwest Venture Partners共同领导了这一轮投资，RiverVest Venture Partners、Red Tree Venture Capital、abrdn Inc.管理的基金、Ysios Capital、Longwood Fund、Eight Roads Ventures和现有创始投资者Pivotal Life Sciences也参与了这一轮投资。

Since its inception in 2019, the Company has raised over $220 million..

自2019年成立以来，该公司已募集资金超过2.2亿美元。

Funding from the Series B round will propel the advancement of the Company’s pipeline through multiple stages of clinical development. The Company is developing therapies for the treatment of diseases with significant unmet medical need including anxiety disorders, depression, posttraumatic stress disorder, and rare neurodegenerative diseases..

B轮融资将推动该公司在多个临床开发阶段的管道发展。该公司正在开发治疗严重未满足医疗需求的疾病的疗法，包括焦虑症、抑郁症、创伤后应激障碍和罕见的神经退行性疾病。

“With strong financial backing from highly sophisticated and dedicated life science investors, we are well positioned to deliver multiple value-creating milestones. Notably, we look forward to completing our ongoing ENX-102 phase 2 study in generalized anxiety disorder and advancing the rest of our pipeline into clinical development,” said Vikram Sudarsan, Ph.D., president and CEO of Engrail Therapeutics.

Vikram Sudarsan博士说：“在高度成熟和专注的生命科学投资者的强大财务支持下，我们有能力实现多个创造价值的里程碑。值得注意的是，我们期待着完成正在进行的ENX-102广泛性焦虑症2期研究，并将剩下的管道推进临床开发。”Engrail Therapeutics总裁兼首席执行官。

“Engrail was fortunate to have been incubated under a tremendous commitment from Pivotal Life Sciences. We are excited to start the next chapter of our journey with some of the best thought partners in neuroscience and life sciences investing in our success.”.

“Engrail很幸运地在关键生命科学的巨大承诺下孵化。我们很高兴与神经科学和生命科学领域的一些最佳思想合作伙伴一起开始我们旅程的下一章，为我们的成功投资。”

Following this financing, Stacie Weninger, Ph.D. (F-Prime), Jasper Bos, Ph.D. (Forbion), Tiba Aynechi, Ph.D. (Norwest), Niall O’Donnell, Ph.D. (RiverVest), and Heath Lukatch, Ph.D. (Red Tree) have joined the Engrail board of directors.

融资后，Stacie Weninger博士（F-Prime）、Jasper Bos博士（Forbion）、Tiba Aynechi博士（Norwest）、Niall O'Donnell博士（RiverVest）和Heath Lukatch博士（Red Tree）加入了英国铁路公司董事会。

“We see tremendous potential in Engrail’s pipeline and management team and are excited to participate in their development of transformative therapies for patients,” said Stacie Weninger, Ph.D., board member and president of F-Prime Biomedical Research Initiative.

F-Prime Biomedical Research Initiative董事会成员兼总裁Stacie Weninger博士说：“我们看到Engrail的管道和管理团队具有巨大潜力，很高兴参与他们为患者开发的变革性疗法。”

Peter Bisgaard, chairman of Engrail’s board of directors and managing director at Pivotal Life Sciences added, “We are proud to have started Engrail, which has progressed rapidly from an idea into a clinical-stage neuroscience company within just a few years. We have assembled a strong Series B syndicate that positions the organization well for significant growth and pipeline advancement.”.

Engrail董事会主席兼Pivotal Life Sciences董事总经理彼得·比斯加德（Peter Bisgaard）补充道：“我们很荣幸创办了Engrail，它在短短几年内从一个想法迅速发展成为一家临床阶段的神经科学公司。我们已经组建了一个强大的B系列财团，为该组织的显着增长和管道进步奠定了良好的基础。”

About Engrail Therapeutics

关于Engrail Therapeutics

Engrail is a clinical-stage pharmaceutical company with the aspiration of becoming a leader in neuroscience. Our purpose is to deliver transformational therapies that improve the lives of patients with neuropsychiatric and neurodevelopmental diseases.

Engrail是一家临床阶段制药公司，希望成为神经科学领域的领导者。我们的目的是提供转化疗法，改善神经精神和神经发育疾病患者的生活。